(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002986 A3

(51) International Patent Classification[7]: C07D 471/04, 487/04, 403/08, 473/00, 405/08, A61K 31/41, 31/435, 31/52, A61P 25/00, 9/00, 3/00

(21) International Application Number: PCT/JP2003/008161

(22) International Filing Date: 26 June 2003 (26.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002-190978 28 June 2002 (28.06.2002) JP

(71) Applicant *(for all designated States except US)*: **BANYU PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-3, Nihombashi Honcho 2-Chome, Chou-ku, Tokyo 103-8416 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OTAKE, Norikazu** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD. Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **MORIYA, Minoru** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD. Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **OGINO, Yoshio** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **MATSUDA, Kenji** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., 2-3, Nihonbashi Honcho 2-chome, Chuo-ku, TOKYO 103-8416 (JP). **NAGAE, Yoshikazu** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **KANATANI, Akio** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). **FUKAMI, Takehiro** [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP).

(74) Agent: **IWATANI, Ryo**; Sakurabashi Chiyoda Build., 5F, 1-27, Dojima 2-chome, Kita-ku, Osaka-shi, Osaka 530-0003 (JP).

(81) Designated States *(national)*: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, RU, SC, SG, SY, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, RU, SC, SG, SY, TJ, TM, TN, TT, UA, UZ, VC, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *of inventorship (Rule 4.17(iv)) for US only*


Published:

— *with international search report*

(88) Date of publication of the international search report: 22 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL BENZIMIDAZOLE DERIVATIVES



(I)

(57) Abstract: A compound of the formula (I): (wherein A, B, C and D are independently nitrogen or optionally! I substituted methine; E is nitrogen, methine or hydroxyl, substituted methine; n is 0 or 1; T, U, V and W are independently!, nitrogen or optionally substituted methine; X is -N(SOzR4)-, N (COR5) - or -CO- ; Y is -C (R6) (R7) - , -O- or -N (RS) - provided that the compound (I) when E is nitrogen, n is 0, X is -CO-, and Y is -0 is excluded). is useful as an agent for the treatment of various diseases related to NPY neuropeptide Y.

WO 2004/002986 A3